全文获取类型
收费全文 | 1431624篇 |
免费 | 117649篇 |
国内免费 | 3410篇 |
专业分类
耳鼻咽喉 | 18671篇 |
儿科学 | 47180篇 |
妇产科学 | 41835篇 |
基础医学 | 203194篇 |
口腔科学 | 38223篇 |
临床医学 | 128416篇 |
内科学 | 287726篇 |
皮肤病学 | 33805篇 |
神经病学 | 119306篇 |
特种医学 | 54818篇 |
外国民族医学 | 464篇 |
外科学 | 215242篇 |
综合类 | 33033篇 |
现状与发展 | 4篇 |
一般理论 | 520篇 |
预防医学 | 111800篇 |
眼科学 | 32199篇 |
药学 | 100295篇 |
1篇 | |
中国医学 | 3361篇 |
肿瘤学 | 82590篇 |
出版年
2021年 | 10579篇 |
2019年 | 12318篇 |
2018年 | 17409篇 |
2017年 | 13264篇 |
2016年 | 14837篇 |
2015年 | 16703篇 |
2014年 | 23637篇 |
2013年 | 34798篇 |
2012年 | 47678篇 |
2011年 | 50342篇 |
2010年 | 29535篇 |
2009年 | 28271篇 |
2008年 | 46488篇 |
2007年 | 49133篇 |
2006年 | 49611篇 |
2005年 | 48000篇 |
2004年 | 45781篇 |
2003年 | 43546篇 |
2002年 | 41803篇 |
2001年 | 73155篇 |
2000年 | 74607篇 |
1999年 | 61436篇 |
1998年 | 16339篇 |
1997年 | 14645篇 |
1996年 | 14778篇 |
1995年 | 14930篇 |
1994年 | 13574篇 |
1993年 | 12716篇 |
1992年 | 45942篇 |
1991年 | 43611篇 |
1990年 | 41578篇 |
1989年 | 39640篇 |
1988年 | 36274篇 |
1987年 | 35458篇 |
1986年 | 32947篇 |
1985年 | 31365篇 |
1984年 | 23904篇 |
1983年 | 20093篇 |
1982年 | 12325篇 |
1981年 | 10870篇 |
1979年 | 20721篇 |
1978年 | 14643篇 |
1977年 | 12130篇 |
1976年 | 11384篇 |
1975年 | 11659篇 |
1974年 | 14026篇 |
1973年 | 13566篇 |
1972年 | 12663篇 |
1971年 | 11500篇 |
1970年 | 10929篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献102.
Luis Miguel Jiménez Muñoz Indira Sotelo Díaz Carlos Salgado Rohner Gabriela Cáez Ramirez 《Journal of Culinary Science & Technology》2019,17(2):89-102
Lionfish is an invasive and predatory species with low local consumption due to a lack of culinary knowledge of its preparation. A new way to prepare lionfish was proposed to increase variety and provide added value. The aim of this study was to evaluate the effect of high power ultrasound application on the textural properties measured by the texture profile analysis, sensory attributes, and shape preference of surimi patties (rounded and square) made from lionfish. Patties were prepared using lionfish surimi processed with ultrasound (37 kHz; 150 W), sodium citrate (0.3%), sucrose (1%), and salt (2%). Ultrasound exposure increased the hardness of the patties by 35.1%, decreased cohesiveness by 89.7%, and decreased the chewiness by 49.1%. Results show that high power ultrasound showed potential as an environmentally friendly technology to create surimi as a base for patties with sensory and textural appropriateness, increasing the potential culinary applications of lionfish. 相似文献
103.
104.
Mieke R. Van Bockstal Marie C. Agahozo Linetta B. Koppert Carolien H.M. van Deurzen 《International journal of cancer. Journal international du cancer》2020,146(5):1189-1197
Ductal carcinoma in situ (DCIS) of the breast is a nonobligate precursor of invasive breast cancer, accounting for 20 % of screen-detected breast cancers. Little is known about the natural progression of DCIS because most patients undergo surgery upon diagnosis. Many DCIS patients are likely being overtreated, as it is believed that only around 50 % of DCIS will progress to invasive carcinoma. Robust prognostic markers for progression to invasive carcinoma are lacking. In the past, studies have investigated women who developed a recurrence after breast-conserving surgery (BCS) and compared them with those who did not. However, where there is no recurrence, the patient has probably been adequately treated. The present narrative review advocates a new research strategy, wherein only those patients with a recurrence are studied. Approximately half of the recurrences are invasive cancers, and half are DCIS. So-called “recurrences” are probably most often the result of residual disease. The new approach allows us to ask: why did some residual DCIS evolve to invasive cancers and others not? This novel strategy compares the group of patients that developed in situ recurrence with the group of patients that developed invasive recurrence after BCS. The differences between these groups could then be used to develop a robust risk stratification tool. This tool should estimate the risk of synchronous and metachronous invasive carcinoma when DCIS is diagnosed in a biopsy. Identification of DCIS patients at low risk for developing invasive carcinoma will individualize future therapy and prevent overtreatment. 相似文献
105.
Ki-Yong An Andria R. Morielli Dong-Woo Kang Christine M. Friedenreich Donald C. McKenzie Karen Gelmon John R. Mackey Robert D. Reid Kerry S. Courneya 《International journal of cancer. Journal international du cancer》2020,146(1):150-160
The Combined Aerobic and Resistance Exercise (CARE) Trial compared different types and doses of exercise performed during breast cancer chemotherapy. Here, we report the longer-term follow-up of patient-reported outcomes, health-related fitness and exercise behavior at 6, 12 and 24 months postintervention. A multicenter trial in Canada randomized 301 breast cancer patients initiating chemotherapy to thrice weekly, supervised exercise consisting of a standard dose of 25–30 min of aerobic exercise (STAN; n = 96), a higher dose of 50–60 min of aerobic exercise (HIGH; n = 101) or a combined dose of 50–60 min of aerobic and resistance exercise (COMB; n = 104) performed for the duration of chemotherapy (median of 17 weeks). Primary outcomes were patient-reported outcomes including quality of life, cancer-related symptoms and psychosocial outcomes. Secondary outcomes were objective health-related fitness (assessed at 12 months only) and self-reported exercise behavior. A total of 269 (89.4%) participants completed patient-reported outcomes at all three follow-up time points and 263 (87.4%) completed the health-related fitness assessment at 12-month follow-up. COMB was significantly superior to (i) STAN for sleep quality at 6-month follow-up (p = 0.027); (ii) HIGH for upper body muscular endurance at 12-month follow-up (p = 0.020); and (iii) HIGH for meeting the resistance exercise guideline at 6-month follow-up (p = 0.006). Moreover, self-reported meeting of the combined exercise guideline during follow-up was significantly associated with better patient-reported outcomes and health-related fitness. Performing combined exercise during and after breast cancer chemotherapy may result in better longer-term patient-reported outcomes and health-related fitness compared to performing aerobic exercise alone. 相似文献
106.
107.
Alicia M. Blessing MD PhD Janice M. Santiago-O'Farrill MD PhD Weiqun Mao BS MD Lan Pang BS MD Jing Ning MD PhD Daewoo Pak MD PhD Lakshmi Reddy Bollu MD PhD Philip Rask BS MD LaKesla Iles BS MD Hailing Yang PhD MD Samantha Tran BS MD Ezzeddine Elmir BS MD Geoffrey Bartholomeusz MD PhD Robert Langley MD PhD Zhen Lu MD Robert C. Bast Jr MD 《Cancer》2020,126(15):3579-3592
108.
Mohamed E. Salem J. Nicholas Bodor Alberto Puccini Joanne Xiu Richard M. Goldberg Axel Grothey W. Michael Korn Anthony F. Shields William M Worrilow Edward S. Kim Heinz-Josef Lenz John L. Marshall Michael J. Hall 《International journal of cancer. Journal international du cancer》2020,147(10):2948-2956
Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in a diverse sample of tumors. Hypothesized differences were identified by the protein/gene affected/mutated and the tumor histology/primary site. Overall, 1057 MSI-H tumors were identified from the 32 932 tested. MSI was examined by NGS using 7000+ target microsatellite loci. TMB was calculated using only nonsynonymous missense mutations sequenced with a 592-gene panel; a subset of MSI-H tumors also had MMR IHC performed. Analyses examined TMB by MMR protein heterodimer impacted (loss of MLH1/PMS2 vs. MSH2/MSH6 expression) and gene-specific mutations. The sample was 54.6% female; mean age was 63.5 years. Among IHC tested tumors, loss of co-expression of MLH1/PMS2 was more common (n = 544/705, 77.2%) than loss of MSH2/MSH6 (n = 81/705, 11.5%; P < .0001), and was associated with lower mean TMB (MLH1/PMS2: 25.03 mut/Mb vs MSH2/MSH6 46.83 mut/Mb; P < .0001). TMB also varied by tumor histology: colorectal cancers demonstrating MLH1/PMS2 loss had higher TMBs (33.14 mut/Mb) than endometrial cancers (20.60 mut/Mb) and other tumors (25.59 mut/Mb; P < .0001). MMR gene mutations were detected in 42.0% of tumors; among these, MSH6 mutations were most common (25.7%). MSH6 mutation patterns showed variability by tumor histology and TMB. TMB varies by underlying cause(s) of MSI and tumor histology; this heterogeneity may contribute to differences in response to ICI. 相似文献
109.